Table 4. MLR, NLR and PLR in relation to AEG-specific survival in various stratifications of overall patients and those with types II and III AEG.
| Parameter | MLRa | NLRb | PLRc | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Overall | Siewert type II | Siewert type III | Overall | Siewert type II | Siewert type III | Overall | Siewert type II | Siewert type III | |
| Used no. | 611 | 390 | 221 | 611 | 390 | 221 | 611 | 390 | 221 |
| Comprehensive | 1.26 (0.99-1.59) | 1.06 (0.79-1.43) | 1.69 (1.13-2.54) | 1.26 (1.00-1.60) | 1.03 (0.77-1.39) | 1.84 (1.22-2.78) | 0.99 (0.78-1.25) | 0.87 (0.64-1.17) | 1.27 (0.85-1.91) |
| Gender | |||||||||
| Female | 1.03 (0.59-1.80) | 0.59 (0.27-1.33) | 1.42 (0.61-3.29) | 1.96 (1.08-3.53) | 1.41 (0.64-3.10) | 2.93 (1.03-8.31) | 1.03 (0.58-1.80) | 0.79 (0.38-1.67) | 1.25 (0.52-3.03) |
| Male | 1.33 (1.02-1.73) | 1.18 (0.85-1.63) | 1.71 (1.07-2.75) | 1.16 (0.90-1.51) | 0.98 (0.71-1.35) | 1.69 (1.06-2.70) | 0.98 (0.75-1.27) | 0.86 (0.62-1.19) | 1.33 (0.84-2.11) |
| Age group | |||||||||
| ≤ 63 years | 1.55 (1.11-2.16) | 1.54 (1.00-2.37) | 1.57 (0.93-2.67) | 1.17 (0.84-1.63) | 1.10 (0.71-1.69) | 1.28 (0.75-2.17) | 0.94 (0.68-1.31) | 0.92 (0.60-1.42) | 1.03 (0.61-1.74) |
| > 63 years | 0.98 (0.70-1.37) | 0.74 (0.49-1.12) | 1.74 (0.91-3.33) | 1.32 (0.94-1.85) | 0.93 (0.62-1.41) | 2.94 (1.46-5.89) | 1.08 (0.77-1.53) | 0.84 (0.56-1.27) | 1.99 (1.02-3.87) |
| Siewert classification | |||||||||
| Type II | 1.06 (0.79-1.43) | 1.06 (0.79-1.43) | NA | 1.03 (0.77-1.39) | 1.03 (0.77-1.39) | NA | 0.87 (0.64-1.17) | 0.87 (0.64-1.17) | NA |
| Type III | 1.69 (1.13-2.54) | NA | 1.69 (1.13-2.54) | 1.84 (1.22-2.78) | NA | 1.84 (1.22-2.78) | 1.27 (0.85-1.91) | NA | 1.27 (0.85-1.91) |
| Vessel invasion | |||||||||
| No | 1.23 (0.95-1.60) | 1.11 (0.80-1.53) | 1.49 (0.96-2.32) | 1.17 (0.91-1.52) | 0.96 (0.69-1.33) | 1.70 (1.09-2.67) | 0.90 (0.67-1.17) | 0.80 (0.57-1.11) | 1.12 (0.72-1.74) |
| Yes | 1.49 (0.80-2.78) | 0.95 (0.46-1.97) | 3.50 (1.06-11.51) | 2.08 (1.14-3.80) | 1.58 (0.75-3.32) | 5.11 (1.24-21.16) | 1.60 (0.90-2.84) | 1.26 (0.62-2.55) | 2.94 (0.90-9.64) |
| pTNM stage | |||||||||
| I | 1.44 (0.52-3.95) | 0.66 (0.20-2.10) | NA | 0.67 (0.25-1.82) | 0.82 (0.26-2.58) | 0.32 (0.03-3.72) | 1.60 (0.58-4.43) | 1.60 (0.51-5.02) | 1.03 (0.08-12.78) |
| II | 1.13 (0.62-2.08) | 1.06 (0.51-2.23) | 1.00 (0.33-2.99) | 1.58 (0.87-2.87) | 1.75 (0.85-3.63) | 1.27 (0.45-3.62) | 1.35 (0.75-2.44) | 1.16 (0.55-2.45) | 1.64 (0.57-4.68) |
| III | 1.27 (0.97-1.67) | 1.10 (0.78-1.55) | 1.58 (1.01-2.47) | 1.26 (0.96-1.65) | 0.95 (0.68-1.34) | 2.03 (1.27-3.25) | 0.92 (0.70-1.20) | 0.79 (0.56-1.10) | 1.18 (0.75-1.84) |
Hazard ratios (HRs) of high versus low level of each ratio are presented as point estimate (95% confidence interval) after adjustment of gender, age group, tumor position, vessel invasion, and pTNM stage in each stratification by clinicopathological parameters of the overall patients, patients with type II tumors, and those with type III cancers. HRs were calculated using the multiple Cox regression model with adjustment, and are statistically significant when shown in bold. aMLR > 0.223 vs. MLR ≤ 0.223; bNLR > 2.22 vs. NLR ≤ 2.22; xPLR > 124.4 vs. PLR ≤ 124.4 Abbreviations: MLR, monocyte-lymphocyte ratio; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; NA, not applicable.